View in EDS

452PD - Safety, antitumor activity, and pharmacokinetics (PK) of pamiparib (BGB-290), a PARP1/2 inhibitor, in patients (pts) with advanced solid tumours: Updated phase I dose-escalation/expansion results.

Saved in:
Bibliographic Details
Title: 452PD - Safety, antitumor activity, and pharmacokinetics (PK) of pamiparib (BGB-290), a PARP1/2 inhibitor, in patients (pts) with advanced solid tumours: Updated phase I dose-escalation/expansion results.
Authors: Voskoboynik, M.1 (AUTHOR), Mileshkin, L.2 (AUTHOR), Gan, H.3 (AUTHOR), Millward, M.4 (AUTHOR), Au-Yeung, G.2 (AUTHOR), Meniawy, T.M.4 (AUTHOR), Kichenadasse, G.5 (AUTHOR), Zhang, K.6 (AUTHOR), Zhang, M.7 (AUTHOR), Mu, S.8 (AUTHOR), Lickliter, J.D.1 (AUTHOR)
Source: Annals of Oncology. 2019 Supplement 6, Vol. 30, pv167-v167. 1p.
Database: Academic Search Ultimate
Description
ISSN:09237534
DOI:10.1093/annonc/mdz244.014